Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0178874 (tumor progression)
 40,807 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

From 1971 to 1985, 21 patients received megavoltage external beam radiation therapy at the University of Pittsburgh for control of craniopharyngioma. Minimum tumor doses prescribed to the 95% isodose volume ranged between 51.3 to 70.0 Gy. Median total dose was 60.00 Gy and median dose per fraction was 1.83 Gy. Three deaths occurred from intercurrent disease and no deaths from tumor progression. Actuarial overall survival was 89% and 82% at 5 and 10 years. Actuarial local control was 95% at 5 and 10 years. Radiation related complications included one patient with optic neuropathy, one with brain necrosis, and one that developed optic neuropathy followed by brain necrosis. The high dose group of patients who received a NSD or Neuret equivalent of greater than 60 Gy at 1.8 Gy per fraction had a significantly greater risk of radiation complications (p = .024). The actuarial risk at 5 years for optic neuropathy was 30% and brain necrosis was 12.5% in the high dose group. Tumor control in the high dose group was not shown to be significantly better. Any possible benefit in tumor control in treating patients with craniopharyngioma with doses above 60 Gy at 1.8 Gy per fraction appears to be offset by the increased risk of radiation injury.
 ...
PMID:Megavoltage external beam irradiation of craniopharyngiomas: analysis of tumor control and morbidity. 211 87

The data on combined photon-neutron radiation therapy of brain tumors (23 patients) are presented. Total focal dose (NSD) of photon radiation was 48-60 isoGy; neutron radiation--2.4 Gy (OBE equivalent to gamma radiation of 14.4 Gy). Out of 23 patients, 15 (65.2%) had suffered from tumor disease for a long time which continued after surgery or combined treatment, while 8 (34.8%) were followed up after treatment for primary brain tumor. First symptoms were evaluated. Dehydration therapy was given to 16 (69.6%). Photon- neutron radiation therapy follow-up was up 12 months. Immediate results were assessed every week. The number of complaints went down by approximately 12-15%; improvement was reported in 13 (56.5%), stabilization--9 (39.2%), deterioration--1 (4.8%). According to CT examination of the brain one month later, condition at focal site was unchanged in 17 (73.9%), 10% regression of tumor--6(26.1%). General aggravation of symptoms without roentgenological signs of tumor progression was registered in one case 3 months later. Brain tumor relapsed in still another patient 4 months later. All patients survived 12 months. These indices were 1.5-2 times higher than those for treatment of similar pathology using photon component alone.
 ...
PMID:[Neutron-photon radiotherapy of brain tumors]. 1292 15